外科理论与实践 ›› 2023, Vol. 28 ›› Issue (06): 501-506.doi: 10.16139/j.1007-9610.2023.06.03

• 专家论坛 • 上一篇    下一篇

甲状腺髓样癌病理诊断新进展

刘志艳1(), 余雅玲1, 觉道健一2   

  1. 1.上海交通大学医学院附属第六人民医院病理科,上海 200233
    2.日本和泉市立総合医療センター病理診断科 甲状腺疾患センター,大阪府和泉市 594-0073
  • 收稿日期:2023-11-06 出版日期:2023-11-25 发布日期:2024-03-04
  • 通讯作者: 刘志艳,E-mail:zhiyanliu@shsmu.edu.cn
  • 基金资助:
    国家自然科学基金(81972500);上海市“科技创新行动计划”(23ZR1448200);上海市“科技创新行动计划”(20Z11900304)

Update of pathology in medullary thyroid carcinoma

LIU Zhiyan1(), YU Yaling1, KAKUDO Kennichi2   

  1. 1. Department of Pathology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
    2. Department of Pathology and Thyroid Disease Center, Izumi City General Hospital, Izumi Osaka 594-0073, Japan
  • Received:2023-11-06 Online:2023-11-25 Published:2024-03-04

摘要:

甲状腺髓样癌(medullary thyroid carcinoma, MTC)侵袭性强,转移率、复发率高,在甲状腺恶性肿瘤中相对少见。手术治疗是MTC首选治疗方案,靶向和免疫治疗已逐渐成为MTC新型治疗模式。2022年,第5版世界卫生组织内分泌与神经内分泌肿瘤分类对MTC进行组织学分级,并更新其分子病理特征。本文阐述MTC病理诊断新进展,并着重于组织学分级系统、分子特征和遗传筛查与咨询在MTC复发风险分层及靶向治疗方面的关键作用。

关键词: 甲状腺髓样癌, 组织学分级系统, 基因筛查, 遗传咨询

Abstract:

Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy, which is more aggressive with high metastasis and recurrence rate. Surgical treatment is the preferred treatment option for MTC. Targeted therapy and immunotherapy have gradually become new treatment strategy for MTC. The pathology of MTC was updated in the 5th edition WHO classification of endocrine and neuroendocrine tumor in 2022. This review summarized the update of MTC pathology focusing on the histologic grading schemes, gene screening and genetic counseling.

Key words: Medullary thyroid carcinoma, Histologic grading scheme, Genetic screening, Genetic counseling

中图分类号: